To address this gap, we report an ALK-driven IFS-like neoplasm of the hand, which was managed using a multimodal approach with oral lorlatinib, a tyrosine kinase inhibitor that targets ALK, and conservative surgical resection. This evidence concerns the gene ALK and congenital fibrosarcoma.